New national guidelines issued for type 2 diabetes management in India
City News Mumbai••5 views•2 min read
The Ministry of Health has issued updated national guidelines for the diagnosis, treatment, and monitoring of type 2 diabetes. These guidelines place a new emphasis on patient education, medication management, and lifestyle interventions.
In India, the prevalence of type 2 diabetes is estimated to exceed 77 million in 2023, accounting for more than 70 % of the global burden according to the World Health Organization. To combat this epidemic, the Ministry of Health released the latest guidelines for national diabetes management on August 15 2024.
The purpose of these guidelines is to establish a coordinated approach among physicians, patients, and policymakers. Key changes include a structured module for patient education, clear protocols for drug combinations, and the incorporation of digital tools for monitoring disease progression.
**Key points:** 1. **Diagnosis criteria** – Diabetes confirmed at fasting blood sugar ≥ 100 mg/dL or HbA1c ≥ 5.7 %. 2. **First step** – Lifestyle modifications in diet and physical activity, with consideration of initiating medication within 3–6 months. 3. **Medication management** – Metformin is prioritized as the first‑line drug, with addition of an SGLT‑2 inhibitor or GLP‑1 agonist as needed. 4. **Monitoring** – HbA1c every 3–6 months, and annual assessment of blood pressure and LDL cholesterol. 5. **Patient education** – Empower patients for self‑management through digital platforms and community health workers.
Health and Family Welfare Minister Dr. Rajesh Kumar said, “These guidelines will motivate patients to receive timely treatment and adopt lifestyle changes, thereby reducing the incidence of complications.” He added that the government will implement these standards at primary health centers in both rural and urban areas.
Health experts believe that this step will improve the management of type 2 diabetes and enhance patients’ quality of life. However, some physicians have warned that decisions on drug combinations should be based on individual patient circumstances.
Ultimately, these guidelines represent a significant step toward positioning India among the world’s leading health systems, which will not only benefit patients but also is expected to reduce healthcare costs.
